Copyright
©The Author(s) 2022.
World J Gastrointest Endosc. May 16, 2022; 14(5): 320-334
Published online May 16, 2022. doi: 10.4253/wjge.v14.i5.320
Published online May 16, 2022. doi: 10.4253/wjge.v14.i5.320
Table 3 Relationship between detection of residual tumor and clinicopathological factors
| Detection of residual tumor | |||
| Possible | Impossible | P | |
| All, n (%) | 15 (75) | 5 (25) | |
| Preoperative treatment, n (%) | |||
| NAC | 11 (79) | 3 (21) | |
| CRT | 4 (67) | 2 (33) | 0.613 |
| Macroscopic type after neoadjuvant therapy, n (%) | |||
| Ulcerative and protruding type | 11 (100) | 0 (0) | |
| Superficial and SMT type | 4 (44) | 5 (56) | 0.008 |
| Pathologic tumor size (mm) | |||
| Median (range) | 42 (5-65) | 4 (2-34) | 0.008 |
| Pathological T stage, n (%) | |||
| pT1a/1b | 5 (56) | 4 (44) | |
| pT2/3 | 10 (91) | 1 (9) | 0.127 |
| Pathological response, n (%) | |||
| Grade1 | 12 (92) | 1 (8) | |
| Grade2 | 3 (43) | 4 (57) | 0.031 |
- Citation: Yonemoto S, Uesato M, Nakano A, Murakami K, Toyozumi T, Maruyama T, Suito H, Tamachi T, Kato M, Kainuma S, Matsusaka K, Matsubara H. Why is endosonography insufficient for residual diagnosis after neoadjuvant therapy for esophageal cancer? Solutions using muscle layer evaluation. World J Gastrointest Endosc 2022; 14(5): 320-334
- URL: https://www.wjgnet.com/1948-5190/full/v14/i5/320.htm
- DOI: https://dx.doi.org/10.4253/wjge.v14.i5.320